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Genetic reprogramming of human mammary cells by
environmental
carcinogens released into breast milk
Abstract
Epidemiologic studies indicate that high serum levels of chlorinated pollutants such as dioxins or
pesticides constitute a risk factor for breast cancer in postmenopausal women. This finding has been
attributed to the ability of organochlorine compounds to induce the expression of cytochrome P450
(CYP) enzymes, which are thought to increase the burden of genotoxic metabolites. However, it was not
clear whether the incriminated pollutants accumulate to sufficiently high levels within the human body
to be able to promote significant transcriptional responses. Here, milk samples from nursing mothers
were processed by gel permeation chromatography to isolate complex mixtures of residues containing
both endogenous hormones and lipophilic contaminants of environmental origin. High-density
oligonucleotide microarrays were used to monitor global transcriptional profiles in a human cell line
(MCF7) that represents one of the most frequently used model systems to study breast cancer
biology.We found that all breast milk extracts were able to reprogram the genome of MCF7 cells by
imposing a typically estrogenic expression fingerprint. This estrogenic background was overlapped only
by the induction of transcripts coding for CYP1A1 and, to a minor degree, CYP1B1. The magnitude of
induction of these metabolic enzymes correlated with the respective organochlorine concentrations.
Thus, in support of previous epidemiologic studies, we demonstrate that contaminants released from
human adipose tissue trigger a potentially genotoxic pathway in cells from the mammary gland.
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Abstract: Epidemiologic studies indicate that high serum levels of chlorinated pollutants such as dioxins or pes-
ticides constitute a risk factor for breast cancer in postmenopausal women. This finding has been attributed to
the ability of organochlorine compounds to induce the expression of cytochrome P450 (CYP) enzymes, which are
thought to increase the burden of genotoxic metabolites. However, it was not clear whether the incriminated pollut-
ants accumulate to sufficiently high levels within the human body to be able to promote significant transcriptional
responses. Here, milk samples from nursing mothers were processed by gel permeation chromatography to isolate
complex mixtures of residues containing both endogenous hormones and lipophilic contaminants of environmental
origin. High-density oligonucleotide microarrays were used to monitor global transcriptional profiles in a human
cell line (MCF7) that represents one of the most frequently used model systems to study breast cancer biology.
We found that all breast milk extracts were able to reprogram the genome of MCF7 cells by imposing a typically
estrogenic expression fingerprint. This estrogenic background was overlapped only by the induction of transcripts
coding for CYP1A1 and, to a minor degree, CYP1B1. The magnitude of induction of these metabolic enzymes
correlated with the respective organochlorine concentrations. Thus, in support of previous epidemiologic studies,
we demonstrate that contaminants released from human adipose tissue trigger a potentially genotoxic pathway in
cells from the mammary gland.
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only a fraction of all cases.
[1−3]
There is
also concern regarding the risk associated
with chlorinated organic pollutants com-
monly found in the human body. Examples
of such anthropogenic compounds are the
pesticide 2,2-bis(p-chlorophenyl)-1,1,1-
trichloroethane (DDT), its major metabo-
lite 2,2-bis(p-chlorophenyl)-1,1-dichloro-
ethylene (DDE), industrial chemicals such
as polychlorinated biphenyls (PCBs), as
well as polychlorinated dibenzo-p-dioxins
(PCDDs) and dibenzofurans (PCDFs) aris-
ing from waste incineration.
[4,5]
These chlo-
rinatedchemicalspersist in theenvironment,
magnify along the food chain and, owing
to their lipophilicity, undergo lifelong stor-
age in adipose tissues.
[6]
Because the use of
DDT and PCBs has been banned in many
countries since the 1970s, their concentra-
tion in human tissues is slowly declining.
[7]
An opposite trend of increasing concentra-
tions is observed for polybrominated diphe-
nyl ethers (PBDEs).
[8,9]
The contribution of organochlorine pol-
lutants to the pathogenesis of breast cancer
has been investigated in several studies, (re-
viewed by Tsuda et al.
[10]
). No association
has been found between PCDD/PCDF se-
rum levels and breast cancer.
[11,12]
Similarly,
in most reports no correlation could be de-
tected between breast cancer and the levels
of DDT or DDE.
[13−16]
In contrast, there is
a breast cancer predisposition in postmeno-
pausal women carrying high serum levels
of PCBs together with particular genetic
polymorphisms in CYP1A1, a member of
the cytochrome P450 (CYP) family.
[1,3,17]
As a molecular basis to explain these epide-
miologic findings, it has been proposed that
the up-regulation of CYP1A1, which is in-
ducible by PCBs and other organochlorine
compounds,
[18,19]
may lead to the excessive
formation of reactive metabolites that cause
DNA damage and genetic mutations. This
model predicts that populations with higher
CYP1A1 or CYP1B1 activity would be at
increased risk of breast cancer.
[20]
Two important questions remained un-
answered. First, it has always been inferred
but never demonstrated that organochlorine
compounds reach sufficiently high levels
in the mammary gland to trigger adverse
metabolic effects. Second, it is well known
that humans are usually exposed to a com-
bination of substances, such that multiple
contaminants and metabolites may give rise
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1. Introduction
Breast cancer is the most frequent neoplas-
tic disease in women worldwide. Some fac-
tors modulating the breast cancer risk have
been identified, including obesity, genetic
predisposition, age at menarche and meno-
pause, breastfeeding or postmenopausal
hormone replacements. However, the etiol-
ogy of breast cancer remains largely elu-
sive as these known risk factors explain
doi:10.2533/chimia.2008.410
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to antagonistic interactions that ultimately
mitigate their potential toxicity. For ex-
ample, estrogens have been shown to sup-
press CYP1A1 expression,
[20−22]
suggesting
that the endogenous hormone 17β-estradiol
or estrogen-like contaminants counteract
a critical biological endpoint of dioxins,
PCBs and other CYP inducers. To address
these questions, we sought to examine the
transcriptional changes elicited by complex
mixtures of pollutants that accumulate in the
human body. Although persistent organo-
chlorines display long half-lives,
[23]
consid-
erable amounts are transferred across the
mammary gland,
[6,8]
such that the lipid frac-
tion of breast milk contains contaminants
at concentrations similar to those in other
fatty compartments. As a consequence,
breast milk constitutes a convenient and
non-invasive matrix to assess the internal
burden of lipophilic chemicals.
The transcriptional effects of breast
milk have never been tested on cells from
the mammary gland, but conflicting results
have been observed in standard bioassays.
Some studies showed that breast milk in-
duces the expression of CYP1A1 or analo-
gous reporter genes, primarily the dioxin-
responsive chemically activated luciferase
(DR-CALUX) construct, in rat hepatoma
cells.
[24−26]
However, a more recent contra-
dictory study showed that breast milk, un-
like formula, is unable to induce CYP1A1
expression in human hepatoma cells.
[27]
In
view of these conflicting findings, we used
a representative human cell line derived
from the mammary epithelium to assess
global transcriptional changes induced by
lipophilic breast milk extracts.
2. Results
2.1. Fractionation and Chemical
Analysis
The concentration of environmental pol-
lutants was determined in the lipid phase of
36 milk samples collected from breastfeed-
ing women in 2002. The samples were frac-
tionated by gel permeation chromatography
to obtain residue mixtures comprising a
wide spectrum of organic contaminants.
The analytes detected by gas chromatog-
raphy/high resolution mass spectrometry
include a range of lower and higher chlo-
rinated PCB congeners (from PCB-28 to
PCB-180), 2,3,7,8-substituted PCDDs and
PCDFs, DDT, its metabolite DDE, and the
most prevalent PBDE congeners (from
BDE-28 to PBDE-209). These measure-
ments yielded a group of three samples with
very low contaminant levels (no. 28, 34 and
46), representing the reference group, and a
second group consisting of the most heav-
ily contaminated samples (no. 32, 43 and
45). Compared to the reference group, the
contaminated milk extracts displayed more
than three-fold increased levels of PCBs,
PCDDs and PCDFs (Fig. 1A) and at least
4-fold higher levels of DDT and DDE (Fig.
1B). These two sample groups containing
low and high pollutant levels were used for
the subsequent gene expression studies.
2.2. Genome-wide Expression
Changes
MCF7 cells were incubated directly
with the residue mixtures separated from
breast milk lipids by gel permeation chro-
matography. In triplicate experiments, the
cell culture medium was supplemented with
lipophilic extracts to achieve a contamina-
tion level that is equivalent to that found in
breast milk with a 5% fat content. After 24
h exposures in reconstituted medium, the
cells were harvested and processed for the
genome-wide determination of expression
profiles using DNA microarrays that cover
the sequences of 47’000 human transcripts.
The hybridization results were normal-
ized and subsequently filtered using, as
the statistical cut-off, a significance value
of P <0.05 (ANOVA) in at least one of the
treatment groups. Initially, the data output
was simplified by focusing on transcripts
that, upon treatment with at least one of the
extracts, show a minimal fold change > 5
relative to the solvent controls. This analy-
sis yielded 57 distinct transcripts that were
substantially regulated upon incubation
with breast milk extracts (Fig. 2).
The observed expression changes were
almost exclusively characterized by the in-
duction of genes such as RRM2 (ribonucle-
otide reductase M2), TYMS (thymidylate
synthetase), TK1 (thymidine kinase 1),
CCNA2 (cyclin A2) or MCM10 (minichro-
mosome maintenance 10) that take part in
a well known mitogenic response to estro-
genic stimuli.
[28,29]
The most pronounced
up-regulation of estrogen-dependent fac-
tors was observed after incubation with
extract no. 46, belonging to the reference
group of poorly contaminated samples. A
side-by-side comparison illustrates that
the transcriptional profile induced by this
particular extract is nearly identical to that
elicited by the endogenous 17β-estradiol at
the near saturating concentration of 30 pM
(Fig. 2). This estrogenic expression pattern
was also found after incubation with all oth-
er extracts, although with lower amplitudes
of regulation.
Another comparison of the same 57
transcripts, in the form of a scatter plot,
confirmed that extract no. 46 induces es-
sentially identical transcriptional effects
as 17β-estradiol (Fig. 3A). However, no
direct relationship could be found between
the induction of these estrogen-dependent
transcripts and the presence of major envi-
ronmental contaminants. This lack of a pos-
itive correlation is evidenced by a compari-
son between the RRM2 transcripts and the
concentration of PCBs (Fig. 3B), PCDDs/
PCDFs (Fig. 3C) or DDT/DDE (Fig. 3D).
The distinctive estrogenic background, on
the other hand, prompted us to pool the
breast milk samples in order to measure
their 17β-estradiol content by liquid chro-
matography/tandem mass spectrometry.
This analysis demonstrated that the samples
contained sufficient 17β-estradiol to yield a
mean concentration in the culture medium
of 6 pM or higher (see Discussion).
The only exception to the overall estro-
genic fingerprint induced by breast milk
extracts consisted of an up-regulation of
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Fig. 1. Major chlorinated contaminants in the lipid fraction of breast milk. (A) Concentration of
PCBs (expressed as the sum of congeners 28, 52, 101, 118, 138, 153 and 180) compared to the
concentration of PCDDs and PCDFs (expressed as WHO-TEQ values). (B) Concentration of DDT and
its major metabolite DDE. These graphical representations illustrate the difference between the less
contaminated reference samples (no. 28, 34 and 46) and the more contaminated samples no. 32, 43
and 45. PBDEs were detected at considerably lower concentrations than chlorinated chemicals, i.e.
between 2.2 ng/g lipid in sample no. 28 and 10.0 ng/g in sample no. 34.
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transcripts coding for two members of the
CYP family, i.e. CYP1A1 and CYP1B1.
The strongest induction of these metabolic
enzymes was detected following treatment
with the highly contaminated extract no.
45 (Fig. 2). This induction of CYP1A1 and
CYP1B1, observed in the presence of breast
milk residues, was not decreased by co-in-
cubation with the estrogen antagonist ICI
182,780. In contrast, all other transcripts
regulated by treatment with milk extracts
Fig. 2. Transcriptional changes (mean values of
three independent experiments) resulting from
the incubation of human MCF7 cells with breast
milk extracts or a 17β-estradiol standard (30
pM). The fold changes have been determined
relative to solvent controls incubated with
0.3% (v/v) DMSO. The microarray hybridization
data were analyzed using the GeneSpring
software. Only transcripts with a fold change >
5 (statistical cut-off: P <0.05) in at least one of
the treatment groups are shown. The transcripts
were arranged following their descending order
in the experiments with sample no. 46.
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Fig. 3. Estrogenic response induced in MCF7
cells by breast milk extracts. (A) Scatter plot
comparing 57 estrogen-regulated transcripts
(fold change > 5 in one of the treatment groups; P
<0.05). X-axis, transcriptional induction following
treatment with sample no. 46; Y-axis, induction
of the same transcripts after incubation with
17β-estradiol (30 pM). R, correlation coefﬁcient.
(B) Degree of RRM2 induction in relation to the
PCB concentrations (sum of congeners 28, 52,
101, 118, 138, 153 and 180). (C) RRM2 induction
in relation to PCDD/PCDF levels (expressed as
TEQ concentrations). (D) RRM2 induction plotted
against the concentration of DDT and DDE.
no. 32, 43 and 45, belonging to the highly
contaminated group, were diminished or
suppressed by the addition of ICI 182,780
(Fig. 4). These results confirm that the in-
duction of CYP1A1 and CYP1B1 is inde-
pendent of signaling pathways driven by
estrogen receptors.
Subsequently, the microarray data were
reinvestigated to include transcripts with
less than five-fold changes relative to the
solvent controls. This systematic analysis
revealed that no messengers, other than
those coding for CYP enzymes and a large
number of estrogen-dependent factors,
were significantly (P <0.05) up- or down-
regulated following the treatment with
breast milk extracts (data not shown).
2.3. Validation of Microarray Results
The DNA microarray hybridization
data suggested that CYP1A1 and CYP1B1
constitute the only non-estrogenic tran-
ENDOCRINE DISRUPTORS: HUMAN DISEASE AND DISEASE MODELS 413
CHIMIA 2008, 62, No. 5
scripts in MCF7 cells that are increased af-
ter treatment with the breast milk extracts.
To confirm this finding, real-time reverse
transcriptase-PCR (RT-PCR) assays were
carried out using specific primers. After
normalization with the endogenous glyc-
eraldehyde-3-phosphate dehydrogenase
(GAPDH) control, all expression values
were transformed as the ratio of messenger
levels between treated cells and the sol-
vent controls. The subsequent comparison
of microarray hybridization data with the
respective RT-PCR values showed a high
degree of concordance. For the CYP1A1
transcript, these quantitative PCR deter-
minations yielded a 7.5- to 37.4-fold up-
regulation after incubation of MCF7 cells
with the more contaminated samples no.
32, 43 and 45. In the presence of the less
contaminated reference extracts no. 28,
34 and 46, the CYP1A1 transcript was
induced, on the average, only 3.2-fold.
Moreover, these RT-PCR quantifications
confirmed that the CYP1A1 induction cor-
relates well with the respective concentra-
tions of PCDDs and PCDFs (Fig. 5A) and,
to a lesser extent, with the concentration
of PCBs (Fig. 5B). As expected, there was
no relationship between CYP1A1 induc-
tion and the contamination with DDT/
DDE (Fig. 5C). The CYP1B1 transcripts,
determined by real-time RT-PCR, reached
a 5.1-fold induction level and, as it was the
case for CYP1A1, correlated with the pres-
ence of PCDDs/PCDFs and PCBs, but not
with DDT/DDE (data not shown).
2.4. Analysis by Reporter Gene
Assay
A key player in the induction of CYP
enzymes by xenobiotics is the aryl hydro-
carbon (Ah) receptor.
[30]
Thus, a reporter
gene assay was performed to confirm that
the Ah receptor pathway is stimulated in
the presence of extracts prepared by gel
permeation chromatography. For that
purpose, each residue mixture obtained
from the lipid component of individual
milk samples was used to expose stably
transfected H4IIE cells. This rat hepatoma
cell line carries a chromosomally inte-
grated construct that drives expression of
the firefly luciferase gene under control
of a minimal promoter flanked by dioxin
response elements.
[31]
The Ah receptor
activation was monitored after 24 h treat-
ments by measuring the luciferase activity
in cell lysates. The results of this bioassay,
expressed as 2,3,7,8-tetrachloro-dibenzo-
p-dioxin (TCDD) equivalents in the lipid
fraction, ranged from 73 pg/g in sample
no. 34 to 229 pg/g in sample no. 45. Thus,
the reporter gene assay confirmed that
all tested milk samples contained envi-
ronmental contaminants in sufficiently
abundant concentrations to activate the
Ah receptor.
3. Discussion
Previous epidemiologic studies point
to a role of CYP1A1 polymorphisms in
modulating the predisposition to breast
cancer in postmenopausal women. At
least two different genotypic variants
of this metabolic enzyme have been as-
sociated with cancer risk in women car-
rying high body burdens of PCBs.
[1,3,17]
Fig. 4. Effect of an estrogen receptor antagonist (mean values of triplicate experiments). MCF7 cells
were incubated with extract no. 32 in the absence (orange bars) or in the presence (blue bars) of
ICI 182,780 (100 nM). The fold change is shown for the same 57 transcripts selected in Fig. 2. The
effects of ICI 182,780 were calculated using, as the baseline, control experiments with 100 nM of the
inhibitor alone. The fold induction values along the Y-axis are plotted in a logarithmic scale. Similar
results (suppression of all transcripts except CYP1A1 and CYP1B1) were obtained with extract no.
43 and 45.
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Fig. 5. Real-time RT-PCR validation of CYP1A1
induction. The fold changes were determined
in triplicate PCR assays and plotted against the
respective concentrations of PCDDs/PCDFs
(A), PCBs (B) or DDT/DDE (C). The correlation
coefﬁcients (R) were calculated assuming a
linear relationship.
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CYP1A1 is involved in the biotransforma-
tion of endogenous or exogenous com-
pounds to yield genotoxic metabolites that
cause DNA damage and mutations.
[32−34]
Quinone derivatives produced by cells of
the breast epithelium are an example of
genotoxic molecules resulting from the oxi-
dation of endogenous hormones.
[35]
There
is evidence that polymorphic variants result
in a more inducible CYP1A1 gene
[36]
and
greater biotransformation activity would
enhance the metabolic activation of pro-
carcinogens, thereby increasing the risk of
contracting breast cancer.
[32,33]
PCBs have been shown to induce the
CYP1A1 gene in various experimental sys-
tems.
[30]
However, it was not known wheth-
er chlorinated compounds sequester in the
human body to reach sufficiently elevated
concentrations to be able to stimulate the
expression of CYP1A1 or any other relevant
gene in the mammary gland. CYP1A1 ac-
tivity may be determined for example in
peripheral blood lymphocytes, but these
measurements are susceptible to large in-
dividual variations not related to particular
genotypic differences or exposure levels.
[37]
As a consequence, the purpose of this study
was to examine whether environmental con-
taminants released from the human adipose
tissue are able to induce significant changes
of gene expression in specific target cells.
We took advantage of the fact that the lipid
fraction of breast milk obtained from nurs-
ing mothers reflects the internal burden of
persistent pollutants in adipose tissues.
[6]
One of the best models to study the si-
multaneous effects of Ah and estrogen re-
ceptor ligands is the MCF7 cell line, which
expressesbothAhandestrogenreceptors.
[22]
Also, MCF7 cells were selected for this
study because they originate from the mam-
mary gland, where epithelial cells become
exposed to the contaminants released from
the adipose tissue or milk fat. We pro-
cessed the lipid fraction of milk samples by
gel permeation chromatography to isolate
representative mixtures of a wide spectrum
of contaminants including PCBs, PCDDs,
PCDFs, DDT, DDE and PBDEs, along with
endogenous hormones or metabolites. Our
large-scale transcriptomic analysis dem-
onstrated that these complex lipophilic
extracts induce a predominantly estrogenic
response in mammary cells that is fully at-
tributable to the presence of the endogenous
17β-estradiol (Fig. 2). In fact, 17β-estradiol
is transferred across the mammary gland
generating biologically active concentra-
tions in breast milk
[38]
and physiologic
estrogens also appear in the lipid fraction.
[39]
According to our own measurements by
liquid chromatograpyh/tandem mass spec-
trometry, the final 17β-estradiol concentra-
tion in the cell culture medium, due to its
presence in milk fat, exceeded the in vitro
EC
50
value of 6 pM. Thus, the observed
estrogenic expression profile is induced by
the endogenous hormone rather than exog-
enous factors such as, for example, pesti-
cides or dietary phytoestrogens.
The only non-estrogenic responses aris-
ing from the exposure of MCF7 cells to
breast milk extracts consisted of the induc-
tion of transcripts coding for CYP1A1 and
CYP1B1. Unlike all other transcriptional
changes, the level of these two messen-
gers was not suppressed by co-incubation
with an estrogen receptor antagonist (Fig.
4). Dioxins and PCBs are potent CYP in-
ducers and act mainly through Ah receptor
activation.
[18,40]
This intracellular receptor
undergoes heterodimerization upon ligand
binding and, after translocation into the
nucleus, binds to cognate cis-acting se-
quences located in the 5’-regulatory region
of target genes such as those coding for
major xenobiotic metabolizing enzymes.
Two independent observations confirm
that the lipophilic mixtures isolated from
breast milk act through this pathway. First,
the DR-CALUX reporter assay, based on a
synthetic promoter that detects Ah recep-
tor ligands in a highly selective manner,
[31]
proves that the Ah receptor is activated fol-
lowing treatment with breast milk extracts.
Second, we observed that the amplitude
of CYP1A1 and CYP1B1 induction, de-
termined by real-time RT-PCR, correlates
with the total concentration PCDD/PCDF
(Fig. 5A) and PCBs (Fig. 5B).
The molecular consequences of com-
bined mixtures of dioxins, pesticides and
endogenous hormones are poorly under-
stood.
[22]
To our knowledge, this is the first
report where a large-scale transcriptomic
study has been conducted to monitor the
biological activity of complex substance
mixtures encountered in the human body.
Such a large-scale expression analysis ap-
pears to be particularly useful for the evalu-
ation of mixture effects because it provides
a suitable method to detect simultaneously
the activation or repression of separate path-
ways. Interestingly, we observed a trend of
decreasing estrogenic activity in the more
heavily contaminated samples (Figs. 3B,
3C and 3D), suggesting that the incurred
mixtures of chlorinated compounds may
exert an overall anti-estrogenic activity,
as noted before by Pliskova et al.
[41]
when
analyzing the impact of chlorinated organic
pollutants in the serum of male volunteers.
This view is supported by the known anti-
estrogenic activity of dioxins and dioxin-
like chemicals.
[19]
Thus, the results of our
whole-mixture approach is consistent with
the extracts being able to induce CYP1A1
and CYP1B1 and, at the same time, sup-
press estrogenic responses.
The source of the detected organochlo-
rines and the impact of smoking or other
lifestyle factors in determining the expo-
sure level of the different subjects of this
study are unknown. Nevertheless, to our
knowledge, this is the first proof that a mix-
ture of contaminants accumulating within
individual breast tissues is able to trigger
the transcriptional induction of CYP1A1 and
CYP1B1 in cells derived from the mammary
epithelium. Our results provide a missing
molecular link to explain the role of CYP1A1
polymorphisms in the association between
cancer risk and an elevated level of chlori-
nated chemicals. Based on our findings, it is
likely that the endogenous burden of chlo-
rinated chemicals leads to the induction of
CYP1A1, thus promoting the formation of
genotoxic intermediates or other hazardous
metabolites. This cellular reaction may be
enhanced in the presence of CYP1A1 vari-
ants that are more susceptible to the tran-
scriptional stimulus exerted by chlorinated
compounds.
[36,42]
Conversely, the lack of sig-
nificant associations between these chemi-
cals and breast cancer in some studies (re-
viewed by Laden et al.
[16]
) is likely due to the
fact that only particular genetic risk groups
respond with a strong CYP1A1 induction.
4. Experimental
4.1. Standards
All analytical standards were from the
Cambridge Isotope Laboratories (distribut-
ed by LGC Promochem, Wesel, Germany);
17β-estradiol was purchased from Fluka
(Buchs, Switzerland); 2,3,7,8-tetrachloro-
dibenzo-p-dioxin (TCDD) was from the
NCI Chemical Carcinogen Reference Stan-
dard Repository. The inhibitor ICI 182,780
was purchased from TOCRIS Bioscience
(Avonmouth, UK).
4.2. Human Breast Milk Samples
and Extraction
Breast milk samples (150−250 ml) from
healthy nursing mothers, donated with in-
formed approval between the 5th and 7th
week after delivery, were stored at −20°C
until use. The lipid fraction of each sample
was separated by centrifugation and ex-
tracted as reported previously.
[43]
The lip-
ids were removed by gel permeation chro-
matography on BioBeads S-X3 (Bio-Rad,
Reinach, Switzerland) using cyclohexane/
ethyl acetate as the solvent.
4.3. Analysis of Extracts
Cleanup procedures and gas chroma-
tography/high resolution mass spectrom-
etry (GC/HRMS) were based on methods
described elsewhere.
[43−45]
Isotopically la-
beled analogs of each analyte of interest
were used as internal standards.
4.4. Calculation of Toxic Equivalents
The relative potency of PCDD/PCDF
was expressed as World Health Organization
toxic equivalent (TEQ) concentrations.
[46]
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4.5. Culture of MCF7 Cells and
Treatments
All cell culture media were from Gibco
(Paisley, UK). The MCF7 cell line subtype
BUS (provided by A.M. Soto and C. Son-
nenschein, Tufts University, Boston, USA)
was grown in Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 10%
(v/v) fetal bovine serum (FBS). The antibi-
otics used were 0.1 U/ml penicillin and 0.1
µg/ml streptomycin. The cells were tested
for the absence of Mycoplasma infection
and cultured to 90% confluence at 37 °C
in xenoestrogen-free plastic (Corning Inc.,
Grand Island, USA) under humidified air
containing 5% CO
2
. Before each exposure,
the growth medium was replaced by phenol
red-free DMEM and cells were cultured for
48 h in the presence of 5% charcoal/dex-
tran-stripped FBS. Thereafter, the culture
medium was reconstituted with the level of
lipophilic contaminants that corresponds to
breast milk with an approximate fat content
of 5% (w/v). For that purpose, the residues
obtained by gel permeation chromatogra-
phy of 1.5 g milk fat were dissolved in 90
µl dimethyl sulfoxide (DMSO). Unless oth-
erwise indicated, the resulting DMSO stock
was diluted 333-fold in the cell culture me-
dium to yield a final solvent concentration
of 0.3% (v/v). Control cells were incubated
with 0.3% (v/v) DMSO alone.
4.6. Global Gene Expression
Analysis
After a 24 h incubation with milk ex-
tracts, MCF7 cells were collected by
trypsinization and total RNA was recovered
using the RNeasy mini kit (Qiagen, Hilden,
Germany). RNA quality was determined
by analysis on the Agilent Lab-on-a-chip
Bioanalyzer 2100. Samples with a total
area under the 28S and 18S bands of less
than 65% of the total RNA, as well as a
28S/18S ratio of less than 1.5, were consid-
ered to be degraded and therefore excluded
from microarray analyses. Complementary
DNA and RNA were synthesized using the
cDNAsynthesis and IVT Labeling kits (Af-
fymetrix, Santa Clara, CA), respectively.
The biotin-labeled RNA was fragmented
and hybridized on Human Genome U122
plus 2.0 microarrays (Affymetrix) follow-
ing the manufacturer’s instructions. After
hybridization periods of 16 h, the microar-
rays were processed by automated wash-
ing on the Affymetrix Fluidics Station 450.
Staining of the hybridized probes was per-
formed with fluorescent streptavidin-phy-
coerythrin conjugates (1 mg/ml; Molecular
Probes). The subsequent scanning of DNA
microarrays was carried out on an Affyme-
trix scanner 3000. The data were normal-
ized and analyzed using the GeneSpring
7.3.1 software (Agilent, Palo Alto, CA).
The final results of triplicate experiments
were imported into a Microsoft Excel file
for graphical representation and determina-
tion of correlation coefficients.
4.7. Real-time PCR Assays
PCR validations were carried out to
confirm the DNA microarray hybridization
results. Primers for the selected transcripts
as well as TaqMan probes were obtained
from Applied Biosystems (Foster City,
CA). Briefly, 100 ng of complementary
DNA were mixed with 100 nM of forward
and reverse primers and supplemented with
25 nM TaqMan probe in a final volume
of 25 µl. The reactions were performed in
an ABI PRISM 7700 Sequence Detection
System (Applied Biosystems) in 45 cycles
(95 °C for 15 sec, 60 °C for 1 min) after an
initial 10 min incubation at 95 °C. The fold
change in the expression of each gene was
calculated as described,
[47]
using the glyc-
eraldehyde-3-phosphate dehydrogenase
(GAPDH) transcript as the endogenous
control.
4.8. Reporter Gene Assay
Stably transfected H4IIE cells were
cultured and the DR-CALUX assay was
carried out following the standard operat-
ing procedure provided by BioDetection
Systems (Amsterdam, The Netherlands).
Briefly, rat hepatoma cells were seeded in
microtiter plates (Nunc, Rochester, USA)
with 0.1 ml medium. When a confluence
of at least 95% was reached, 0.1 ml of me-
dium containing milk fat extract was added
to yield a final DMSO concentration of
0.8% (v/v). Solvent controls and a standard
TCDD dose response were included on
each plate. After 24 h exposures, cells were
harvested, lysed and assayed for luciferase
activity on a microplate luminometer (Dyn-
ex, Chantilly, USA). All values were cor-
rected for background luciferase expression
detected in the presence of solvent alone.
The data obtained from the different TCDD
dilutions were fitted to a sigmoidal curve (y
= a
0
/ [1 + (x/a
1
) a
2
]; y = measured activity,
x = TCDD concentration, a
0
= maximum
activity, a
1
= EC50, a
2
= slope factor) and
luciferase activity induced by milk fat ex-
tracts was converted to TCDD equivalents
by interpolation.
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